Overview

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Status:
Recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Alexion Pharmaceuticals

Treatments:

Eculizumab